Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Axsome Therapeutics, Inc. - Common Stock
(NQ:
AXSM
)
148.79
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Axsome Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
Today 7:00 EST
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
Today 6:55 EST
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
November 20, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM
November 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
November 06, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 03, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
October 24, 2025
From
Halper Sadeh LLC
Via
Business Wire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
October 22, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
October 09, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
October 07, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
September 17, 2025
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 04, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
July 21, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
July 21, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
July 09, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
July 07, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
June 20, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
June 18, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
June 16, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
June 11, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
June 10, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
June 09, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 29, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
May 28, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
May 27, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
May 13, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 05, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
May 01, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
April 22, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
